首页> 外文期刊>Chemical biology and drug design >Design and Synthesis of a Tetrahydroisoquinoline- Based Hydroxamate Derivative (ZYJ-34v), An Oral Active Histone Deacetylase Inhibitor with Potent Antitumor Activity
【24h】

Design and Synthesis of a Tetrahydroisoquinoline- Based Hydroxamate Derivative (ZYJ-34v), An Oral Active Histone Deacetylase Inhibitor with Potent Antitumor Activity

机译:基于四氢异喹啉的异羟肟酸酯衍生物(ZYJ-34v)的设计和合成,该衍生物是具有有效抗肿瘤活性的口服活性组蛋白脱乙酰基酶抑制剂

获取原文
获取原文并翻译 | 示例
           

摘要

In our previous study, we developed a novel series of tetrahydroisoquinoline-based hydroxamic acid derivatives as histone deacetylase inhibitors (Bioorg Med Chem, 2010, 18, 1761-1772; J Med Chem, 2011, 54,2823-2838), among which, compound ZYJ-34c (1) was identified and validated as the most potent one with marked in vitro and in vivo antitumor potency (J Med Chem, 2011, 54, 5532-5539.). Herein, further modification in 1 afforded another oral active analog ZYJ-34v (2) with simplified structure and lower molecular weight. Biological evaluation of compound 2 showed efficacious inhibition against histone deacetylase 1, 2,3, and 6, which was confirmed by Western blot analysis results. Most importantly, compound 2 exhibited similar even more potent in vitro and in vivo antitumor activities relative to the approved histone deacetylase inhibitor SAHA.
机译:在我们之前的研究中,我们开发了一系列新的基于四氢异喹啉的异羟肟酸衍生物作为组蛋白脱乙酰基酶抑制剂(Bioorg Med Chem,2010,18,1761-1772; J Med Chem,2011,54,2823-2838),化合物ZYJ-34c(1)被鉴定为最有效的化合物,具有明显的体外和体内抗肿瘤能力(J Med Chem,2011,54,5532-5539。)。在此,在1中的进一步修饰提供了具有简化的结构和较低的分子量的另一种口服活性类似物ZYJ-34v(2)。化合物2的生物学评估显示出对组蛋白脱乙酰基酶1、2、3和6的有效抑制作用,这已通过蛋白质印迹分析结果得到证实。最重要的是,相对于批准的组蛋白脱乙酰基酶抑制剂SAHA,化合物2在体外和体内的抗肿瘤活性更强。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号